JCR Pharmaceuticals Co., Ltd.

Tokyo Stock Exchange 4552.T

JCR Pharmaceuticals Co., Ltd. Current Liabilities for the year ending March 31, 2024: USD 199.10 M

JCR Pharmaceuticals Co., Ltd. Current Liabilities is USD 199.10 M for the year ending March 31, 2024, a -26.03% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

JCR Pharmaceuticals Co., Ltd. Current Liabilities for the year ending March 31, 2023 was USD 269.18 M, a -22.08% change year over year.
JCR Pharmaceuticals Co., Ltd. Current Liabilities for the year ending March 31, 2022 was USD 345.47 M, a 31.80% change year over year.
JCR Pharmaceuticals Co., Ltd. Current Liabilities for the year ending March 31, 2021 was USD 262.12 M, a 170.16% change year over year.
JCR Pharmaceuticals Co., Ltd. Current Liabilities for the year ending March 31, 2020 was USD 97.03 M, a 23.88% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Tokyo Stock Exchange: 4552.T

JCR Pharmaceuticals Co., Ltd.

CEO	Mr. Shin Ashida
IPO Date	Nov. 17, 2005
Location	Japan
Headquarters	3-19 Kasuga-cho
Employees	934
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Pharmaceuticals Vaccines

Description

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Key trends

Past 5 years